ArticleNeuro-oncology advances
Glioblastoma in Puerto Rico: A 21-year population-based study.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma (GBM) is a highly aggressive malignancy and the most common primary malignant brain tumor in adults, with significant variations in incidence and outcomes across different populations. Despite extensive research in the United States (U.S.), there is limited data on GBM epidemiology in Puerto Rico, a U.S. commonwealth with a unique demographic and healthcare system. This study aims to provide the first comprehensive population-based analysis of GBM in Puerto Rico, focusing on incidence, demographics, and geographic distribution. Methods: We performed a retrospective study of 1,423 GBM cases diagnosed in Puerto Rico from 2000 to 2020, including 1,334 cases with histopathologically confirmed diagnoses, utilizing data from the Puerto Rico Central Cancer Registry. Demographic, clinical, and geographic variables were analyzed to identify epidemiological patterns and treatment trends. Statistical analyses included age-adjusted incidence rates, temporal trends, and geolocation mapping. Results: The average age-adjusted incidence rate (AAAIR) of GBM in Puerto Rico was 1.78 per 100,000 people. The highest incidence was observed in the 65-74 age group (6.71 per 100,000). Municipalities such as Moca, Cayey, and San Sebastián exhibited the highest incidence rates, while Culebra reported no cases. A significant upward trend in GBM incidence was observed, with an annual percentage change (APC) of 4.85% (95% CI: 3.66%-6.04%). Conclusion: This study highlights unique epidemiological patterns of GBM in Puerto Rico, including lower incidence rates compared to the U.S. mainland and significant geographic variations. The findings underscore the need for further research into environmental, genetic, and socioeconomic factors influencing GBM in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.